The Di Bella Method (DBM) in the treatment of prostate cancer

A preliminary retrospective study of 16 patients and a review of the literature

Giuseppe Di Bella, Fabrizio Mascia, Biagio Colori

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: To evaluate the objective clinical response and the safety of the combined administration of somatostatin, melatonin, retinoids, vitamin D3, dopamine subtype 2 receptor (D2R) agonists and low doses of cyclophosphamide, associated with androgen ablation, in patients with a histological diagnosis of prostate adenocarcinoma (Pac). MATERIALS AND METHODS: The clinical data of 30 patients with non-invasive and metastatic prostate cancer, who attended our institution over a period of more than 5 years, were retrospectively reviewed. RESULTS: 16 patients satisfied the evaluation criteria. Median age: 64 years. Disease stages: 8 patients (50%) were in Stage II. For advanced stages (Stage IV), secondary lesions were located in the bones and lymph nodes. Taken together, an overall objective response (OR) [Complete response (CR) + Partial Response (PR)] was achieved in 69% of the patients, with 88% of objective clinical benefit [CR+PR+SD]. For local Prostate Cancer group, an OR was achieved in 87.5% of patients (7 cases; 53-98; 95% CI), with CR in 62.5% (5 cases, 31-86; 95% CI). In metastatic disease, the OR was 50% (4 cases; 21-78; 95% CI), with a 20% of CR (2 cases; 7-59; 95% CI) and 75% of clinical benefit. CONCLUSIONS: This preliminary study shows that patients with early and advanced forms of prostate cancer, not previously treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit with the protocol foreseen by the Di Bella Method. Further clinical investigations are strongly recommended.

Original languageEnglish
Pages (from-to)523-528
Number of pages6
JournalNeuroendocrinology Letters
Volume34
Issue number6
Publication statusPublished - 2013

Fingerprint

Prostatic Neoplasms
Retrospective Studies
Therapeutics
Cholecalciferol
Retinoids
Melatonin
Somatostatin
Cyclophosphamide
Androgens
Prostate
Dopamine
Adenocarcinoma
Radiotherapy
Lymph Nodes
Safety
Bone and Bones

Keywords

  • Androgen deprivation
  • Bromocriptine
  • Cabergoline
  • Melatonin
  • Prostate cancer
  • Retinoids
  • Somatostatin/octreotide
  • Vitamins E, D3, C

ASJC Scopus subject areas

  • Endocrinology
  • Endocrine and Autonomic Systems
  • Endocrinology, Diabetes and Metabolism
  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology

Cite this

The Di Bella Method (DBM) in the treatment of prostate cancer : A preliminary retrospective study of 16 patients and a review of the literature. / Di Bella, Giuseppe; Mascia, Fabrizio; Colori, Biagio.

In: Neuroendocrinology Letters, Vol. 34, No. 6, 2013, p. 523-528.

Research output: Contribution to journalArticle

@article{98cd755f8d634d9992074e395ef5ab8d,
title = "The Di Bella Method (DBM) in the treatment of prostate cancer: A preliminary retrospective study of 16 patients and a review of the literature",
abstract = "OBJECTIVE: To evaluate the objective clinical response and the safety of the combined administration of somatostatin, melatonin, retinoids, vitamin D3, dopamine subtype 2 receptor (D2R) agonists and low doses of cyclophosphamide, associated with androgen ablation, in patients with a histological diagnosis of prostate adenocarcinoma (Pac). MATERIALS AND METHODS: The clinical data of 30 patients with non-invasive and metastatic prostate cancer, who attended our institution over a period of more than 5 years, were retrospectively reviewed. RESULTS: 16 patients satisfied the evaluation criteria. Median age: 64 years. Disease stages: 8 patients (50{\%}) were in Stage II. For advanced stages (Stage IV), secondary lesions were located in the bones and lymph nodes. Taken together, an overall objective response (OR) [Complete response (CR) + Partial Response (PR)] was achieved in 69{\%} of the patients, with 88{\%} of objective clinical benefit [CR+PR+SD]. For local Prostate Cancer group, an OR was achieved in 87.5{\%} of patients (7 cases; 53-98; 95{\%} CI), with CR in 62.5{\%} (5 cases, 31-86; 95{\%} CI). In metastatic disease, the OR was 50{\%} (4 cases; 21-78; 95{\%} CI), with a 20{\%} of CR (2 cases; 7-59; 95{\%} CI) and 75{\%} of clinical benefit. CONCLUSIONS: This preliminary study shows that patients with early and advanced forms of prostate cancer, not previously treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit with the protocol foreseen by the Di Bella Method. Further clinical investigations are strongly recommended.",
keywords = "Androgen deprivation, Bromocriptine, Cabergoline, Melatonin, Prostate cancer, Retinoids, Somatostatin/octreotide, Vitamins E, D3, C",
author = "{Di Bella}, Giuseppe and Fabrizio Mascia and Biagio Colori",
year = "2013",
language = "English",
volume = "34",
pages = "523--528",
journal = "Neuroendocrinology Letters",
issn = "0172-780X",
publisher = "Maghira and Maas Publications",
number = "6",

}

TY - JOUR

T1 - The Di Bella Method (DBM) in the treatment of prostate cancer

T2 - A preliminary retrospective study of 16 patients and a review of the literature

AU - Di Bella, Giuseppe

AU - Mascia, Fabrizio

AU - Colori, Biagio

PY - 2013

Y1 - 2013

N2 - OBJECTIVE: To evaluate the objective clinical response and the safety of the combined administration of somatostatin, melatonin, retinoids, vitamin D3, dopamine subtype 2 receptor (D2R) agonists and low doses of cyclophosphamide, associated with androgen ablation, in patients with a histological diagnosis of prostate adenocarcinoma (Pac). MATERIALS AND METHODS: The clinical data of 30 patients with non-invasive and metastatic prostate cancer, who attended our institution over a period of more than 5 years, were retrospectively reviewed. RESULTS: 16 patients satisfied the evaluation criteria. Median age: 64 years. Disease stages: 8 patients (50%) were in Stage II. For advanced stages (Stage IV), secondary lesions were located in the bones and lymph nodes. Taken together, an overall objective response (OR) [Complete response (CR) + Partial Response (PR)] was achieved in 69% of the patients, with 88% of objective clinical benefit [CR+PR+SD]. For local Prostate Cancer group, an OR was achieved in 87.5% of patients (7 cases; 53-98; 95% CI), with CR in 62.5% (5 cases, 31-86; 95% CI). In metastatic disease, the OR was 50% (4 cases; 21-78; 95% CI), with a 20% of CR (2 cases; 7-59; 95% CI) and 75% of clinical benefit. CONCLUSIONS: This preliminary study shows that patients with early and advanced forms of prostate cancer, not previously treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit with the protocol foreseen by the Di Bella Method. Further clinical investigations are strongly recommended.

AB - OBJECTIVE: To evaluate the objective clinical response and the safety of the combined administration of somatostatin, melatonin, retinoids, vitamin D3, dopamine subtype 2 receptor (D2R) agonists and low doses of cyclophosphamide, associated with androgen ablation, in patients with a histological diagnosis of prostate adenocarcinoma (Pac). MATERIALS AND METHODS: The clinical data of 30 patients with non-invasive and metastatic prostate cancer, who attended our institution over a period of more than 5 years, were retrospectively reviewed. RESULTS: 16 patients satisfied the evaluation criteria. Median age: 64 years. Disease stages: 8 patients (50%) were in Stage II. For advanced stages (Stage IV), secondary lesions were located in the bones and lymph nodes. Taken together, an overall objective response (OR) [Complete response (CR) + Partial Response (PR)] was achieved in 69% of the patients, with 88% of objective clinical benefit [CR+PR+SD]. For local Prostate Cancer group, an OR was achieved in 87.5% of patients (7 cases; 53-98; 95% CI), with CR in 62.5% (5 cases, 31-86; 95% CI). In metastatic disease, the OR was 50% (4 cases; 21-78; 95% CI), with a 20% of CR (2 cases; 7-59; 95% CI) and 75% of clinical benefit. CONCLUSIONS: This preliminary study shows that patients with early and advanced forms of prostate cancer, not previously treated by surgery and/or chemo-radiotherapy, can achieve a more than positive clinical benefit with the protocol foreseen by the Di Bella Method. Further clinical investigations are strongly recommended.

KW - Androgen deprivation

KW - Bromocriptine

KW - Cabergoline

KW - Melatonin

KW - Prostate cancer

KW - Retinoids

KW - Somatostatin/octreotide

KW - Vitamins E, D3, C

UR - http://www.scopus.com/inward/record.url?scp=84893066177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893066177&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 523

EP - 528

JO - Neuroendocrinology Letters

JF - Neuroendocrinology Letters

SN - 0172-780X

IS - 6

ER -